CES 2026 was held in Las Vegas, United States, from January 6 to 9, bringing together approximately 4,300 companies from more than 160 countries. Among the participants, NTL HEALTHCARE stood out as an AI healthcare company with demonstrated real-world clinical applications.
■ Vietnam Becomes the First to Prioritize AI-powered Cervical Cancer Screening as a Primary Step
NTL HEALTHCARE’s AI-powered cervical cancer screening technology is currently implemented within the clinical workflows in Vietnam. The system is prioritized as a primary triage step in cervical cancer screening, followed by additional tests such as cytology (Pap tests) or HPV testing when required.
This development is particularly significant as it reflects the introduction of a new clinical protocol in which AI-powered screening is prioritized as the primary step, rather than cytology (Pap tests).
Under the current protocol, patients first undergo AI-powered cervical cancer screening upon visit, followed by additional tests such as cytology (pap tests) or HPV testing when appropriate. This screening approach enables both efficient resource utilization and reduced patient burden by quickly identifying normal cases and directing medical resources toward high-risk groups.
According to clinical implementation standards at local hospitals, the cost of AI-powered cervical cancer screening is approximately 30-50% of that of conventional cytology or HPV testing. In addition, results are available within seconds, supporting timely clinical decision-making for healthcare providers and improving operational efficiency.
■ A Distinctive Approach: AI Applied at the Point of Care
A key factor behind this CES Innovation Award recognition is NTL HEALTHCARE’s on-device AI cervical cancer screening system, CerviCARE® AI. The system is designed to perform artificial intelligence analysis directly on the device without reliance on cloud servers, allowing it to be considered for use even in environments with unstable internet connectivity.
This addresses the network dependency inherent in conventional cloud-based AI medical systems and is regarded as a case in which the technological direction was refined through practical operational experience in clinical settings in Vietnam. Building on this experience, NTL HEALTHCARE has presented a Point-of-Care AI screening model designed for real-world clinical applications.
■ Technological Strength Driving Global Expansion Potential
The CES Innovation Awards place importance not only on the level of technological completeness, but also on the real-world problem-solving capability and societal impact. The CES judging panel appears to have placed particular emphasis on the fact that NTL HEALTHCARE’s technology has moved beyond the research or demonstration stage and is being actively utilized in clinical settings in Vietnam.
In particular, examples demonstrating how AI technology can complement screening frameworks in environments where gaps in medical infrastructure exist have emerged as a key area of interest within the global healthcare community. In this context, the CES judging panel noted that CerviCARE® AI presents a technological approach that takes medical equity into consideration.
Built on this technological foundation, the Vietnam case is regarded as a representative model illustrating the potential for future expansion into global public health initiatives and overseas healthcare markets.
■ Scaling a Vietnam-validated Model to the Global Stage
NTL HEALTHCARE has established a collaborative framework for AI-powered cervical cancer screening technology through a tripartite memorandum of understanding (MOU) signed with a local partner in Vietnam and Hung Vuong Hospital. In collaboration with KOICA, the company has carried out large-scale research initiatives, as well as technical training programs for local healthcare professionals, guided by a shared vision of contributing to the World Health Organization’s goal of eliminating cervical cancer by 2030.
Kim Taehee, CEO of NTL HEALTHCARE, stated, “CerviCARE AI goes beyond the adoption of technology to fundamentally transform the accessibility and structure of cervical cancer screening.” She added, “Building on its validation in Vietnam, we aim to drive meaningful change in global public health and women’s healthcare.”
[글로벌에픽 이성수 CP / lss@globalepic.co.kr]
<저작권자 ©GLOBALEPIC 무단 전재 및 재배포 금지>
